FaresAlsawahMD
Internal Medicine • Ann Arbor, MIHospital Medicine/Hospitalist, Hematology/Oncology
Karmanos Hematology/Oncology Fellow
Dr. Alsawah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
3RD floor Taubman CTR Recp B
Ann Arbor, MI 48109Phone+1 734-936-5582
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2019
Loyola University Medical CenterResidency, Internal Medicine, 2017
Wayne State University School of MedicineClass of 2014
Certifications & Licensure
MI State Medical License 2021 - 2027
IL State Medical License 2014 - 2017- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 12 citationsSpotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung CancerIbrahim Azar, Samer Alkassis, Jami Fukui, Fares Alsawah, Kalub Fedak
Lung Cancer. 2021-10-07 - 6 citationsIntrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemiaFares Alsawah, Lydia L. Benitez, Sarah Choi, Bernard L. Marini, Anthony J. Perissinotti
Blood Advances. 2019-11-12 - 186 citationsRuxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial.Asra Ahmed, Samuel A. Merrill, Fares Alsawah, Paula L. Bockenstedt, Erica L. Campagnaro
The Lancet. Haematology. 2019-09-16
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
